

WO 00/62071

PCT/EP00/03347

1

SEQUENCE PROTOCOL

<110> Willex Biotechnology GmbH

<120> Diagnostic and therapeutic use of antibodies
 against the urokinase receptor

<130> 19116PEP

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 354

<212> DNA

<213> artificial sequence

<220>

<223> description of artificial sequence:
 phage sequence

<220>

<221> CDS

<222> (1)..(354)

<400> 1

cag gtg caa ctg cag cag tca gga cct gag ttg gtg aag cct ggg gct 48
 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

tta gtg aag ata tcc tgc aag gct tct ggt tac agt ttc aca agc tac 96
 Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30

gat ata aat tgg gtg aag cgg agg cct gga cag gga ctt gag tgg att 144
 Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

gga tgg att ttt cct gga gat ggt agt acc aat tac aat gag aaa ttc 192
 Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

aag gac aag gcc aca ctg act gct gac aaa tcc tcc agc aca gcc tac 240
 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

2

65

70

75

80

atg cag ctc aac agc ctg act tct gag aac tct gca gtc tat ttc tgt 288
 Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
 85 90 95

gca aga gat gga agt atg ggg ggg ttt gac tac tgg ggc caa ggg acc 336
 Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

acg gtc acc gtc tcc tca 354
 Thr Val Thr Val Ser Ser
 115

<210> 2

<211> 118

<212> PRT

<213> artificial sequence

<223> description of artificial sequence:
 phage sequence

<400> 2

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30

Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Thr Val Thr Val Ser Ser
 115

WO 00/62071

PCT/EP00/03347

3

<210> 3

<211> 324

<212> DNA

<213> artificial sequence

<220>

<221> CDS

<222> (1)..(324)

<220>

<223> description of artificial sequence:
phage sequence

<400> 3

gat gtt ttg atg acc caa act cca aaa ttc atg tcc aca tca gta gga	48
Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly	
1 5 10 15	

gac agg gtc agc atc acc tgc aag gcc agt cag aat gtt cgt act act	96
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr	
20 25 30	

gta gcc tgg tat caa gag aaa cca ggg cag tct cct aaa gca ctg att	144
Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile	
35 40 45	

tac ttg gca tcc aac cgg cac act gga gtc cct gat cgc ttc aca ggc	192
Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly	
50 55 60	

agt gga tct gga aca gat ttc act ctc acc att agc aat gtg caa tct	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser	
65 70 75 80	

gaa gac ctg gca gat tat ttc tgt ctg caa cat tgg aat tat ccg tac	288
Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr	
85 90 95	

acg ttc gga ggg ggc acc aag ctg gaa atc aaa cgg	324
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg	
100 105	

<210> 4

<211> 108

<212> PRT

<213> artificial sequence

<223> description of artificial sequence:

WO 00/62071

PCT/EP00/03347

4

phage sequence

<400> 4

Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly

1

5

10

15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr

20

25

30

Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile

35

40

45

Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly

50

55

60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser

65

70

75

80

Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr

85

90

95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

100

105

WO 00/62071

PCT/EP00/03347

1

SEQUENZPROTOKOLL

<110> Willex Biotechnology GmbH

<120> Diagnostischer und therapeutischer Einsatz von
Antikörpern gegen den Urokinase-Rezeptor

<130> 19116PEP

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 354

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:
Phagensequenz

<220>

<221> CDS

<222> (1)..(354)

<400> 1

cag	gtg	caa	ctg	cag	cag	tca	gga	cct	gag	ttg	gtg	aag	cct	ggg	gct	48
Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	Gly	Ala	
1				5					10					15		

tta	gtg	aag	ata	tcc	tgc	aag	gct	tct	ggt	tac	agt	ttc	aca	agc	tac	96
Leu	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe	Thr	Ser	Tyr	
			20					25					30			

gat	ata	aat	tgg	gtg	aag	cgg	agg	cct	gga	cag	gga	ctt	gag	tgg	att	144
Asp	Ile	Asn	Trp	Val	Lys	Arg	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile	
		35					40					45				

gga	tgg	att	ttt	cct	gga	gat	ggt	agt	acc	aat	tac	aat	gag	aaa	ttc	192
Gly	Trp	Ile	Phe	Pro	Gly	Asp	Gly	Ser	Thr	Asn	Tyr	Asn	Glu	Lys	Phe	
	50					55					60					

aag	gac	aag	gcc	aca	ctg	act	gct	gac	aaa	tcc	tcc	agc	aca	gcc	tac	240
Lys	Asp	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	

WO 00/62071

PCT/EP00/03347

2

65	70	75	80	
atg cag ctc aac agc ctg act tct gag aac tct gca gtc tat ttc tgt				288
Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys				
	85	90	95	
gca aga gat gga agt atg ggg ggg ttt gac tac tgg ggc caa ggg acc				336
Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr				
	100	105	110	
acg gtc acc gtc tcc tca				354
Thr Val Thr Val Ser Ser				
	115			

<210> 2

<211> 118

<212> PRT

<213> Künstliche Sequenz

<223> Beschreibung der künstlichen Sequenz:
Phagensequenz

<400> 2

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30

Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Thr Val Thr Val Ser Ser
115

WO 00/62071

PCT/EP00/03347

3

<210> 3
 <211> 324
 <212> DNA
 <213> Künstliche Sequenz

<220>
 <221> CDS
 <222> (1)..(324)

<220>
 <223> Beschreibung der künstlichen Sequenz:
 Phagensequenz

<400> 3
 gat gtt ttg atg acc caa act cca aaa ttc atg tcc aca tca gta gga 48
 Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly
 1 5 10 15
 gac agg gtc agc atc acc tgc aag gcc agt cag aat gtt cgt act act 96
 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr
 20 25 30
 gta gcc tgg tat caa gag aaa cca ggg cag tct cct aaa gca ctg att 144
 Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
 35 40 45
 tac ttg gca tcc aac cgg cac act gga gtc cct gat cgc ttc aca ggc 192
 Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60
 agt gga tct gga aca gat ttc act ctc acc att agc aat gtg caa tct 240
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
 65 70 75 80
 gaa gac ctg gca gat tat ttc tgt ctg caa cat tgg aat tat ccg tac 288
 Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr
 85 90 95
 acg ttc gga ggg ggc acc aag ctg gaa atc aaa cgg 324
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 100 105

<210> 4
 <211> 108
 <212> PRT
 <213> Künstliche Sequenz
 <223> Beschreibung der künstlichen Sequenz:

WO 00/62071

PCT/EP00/03347

4

Phagensequenz

<400> 4

Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr
20 25 30

Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
35 40 45

Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
65 70 75 80

Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105